Glaukos Corporation (GKOS) Tops Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
February 22, 2022 4:05 PM ESTSAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021. Key highlights include:
Net sales of $73.2 million in Q4 2021. Glaucoma net sales of $57.1 million and Corneal Health net sales of $16.2 million in Q4 2021. Gross margin of approximately 77% and non-GAAP gross margin of approximately 85% in Q4 2021. Operating expenses of $74.2 million and non-GAAP... More